Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPB-092 in Relapsed or Refractory Acute Myeloid Leukemia
NCT07137637Phase 1Recruiting
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HPB-092 in acute myeloid leukemia (AML). Primary endpoints: Adverse Events and Treatment-Emergent Adverse Events up to 24 months, Dose-Limiting Toxicity at 28 days and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
HPB-092
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07137637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07137637.